IMUNON, Inc. announced on September 19, 2025, that new translational data from its Phase 2 OVATION 2 Study of IMNN-001 will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research. The conference, focused on Advances in Ovarian Cancer Research, is being held from September 19-21, 2025, in Denver, Colorado.
The abstract, titled 'IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer (EOC),' will be presented by Dr. Douglas V. Faller, IMUNON's Chief Medical Officer. This data demonstrates IMNN-001's ability to recruit CD8+ T cells, macrophages, and dendritic cells into the tumor microenvironment while decreasing Treg suppressor cells.
This scientific presentation further supports the unprecedented overall survival data from the Phase 2 study and the ongoing pivotal Phase 3 OVATION 3 trial, which is currently enrolling patients at four trial sites, with up to 46 additional sites under consideration. The findings reinforce IMNN-001's potential as a transformative therapy for advanced ovarian cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.